Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.44 |
| ▸ | PRKACA | P17612 | 6/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16328751 | 0.97 | TLR2 (0.42) | ROCK2PRKACAAKT3TLR2GLP1R | |
| SCHEMBL12892897 | 0.92 | GLP1R (0.39) | ROCK2PRKACAAKT3TLR2GLP1R | |
| SCHEMBL16328767 | 0.91 | TLR2 (0.42) | ROCK2PRKACAAKT3TLR2GLP1R | |
| SCHEMBL12892973 | 0.90 | TLR2 (0.41) | ROCK2PRKACAAKT3TLR2GLP1R | |
| SCHEMBL12893030 | 0.88 | ROCK2 (0.45) | ROCK2PRKACAAKT3TLR2GLP1R | |
| SCHEMBL25825650 | 0.86 | GLP1R (0.51) | TLR2GLP1R | |
| SCHEMBL13753618 | 0.86 | GLP1R (0.51) | TLR2GLP1R | |
| SCHEMBL12417564 | 0.85 | PLG (0.34) | ROCK2PRKACAAKT3TLR2GLP1R | |
| SCHEMBL16329599 | 0.84 | GLP1R (0.51) | GLP1R | |
| SCHEMBL16329790 | 0.84 | GLP1R (0.51) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879588-B2 | Protein-proteophore complexes | ASCENDIS PHARMA A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20070020224-A1 | Protein-proteophore complexes | ASCENDIS PHARMA GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070020224-A1 | Protein-proteophore complexes | ASCENDIS PHARMA GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020224-A1 | Protein-proteophore complexes | PSMG3, PSME1, PSMD11 | ROCK2 3836/4885PRKACA 3578/4885AKT3 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.